Conversely, each of the WEE1 inhibitors, adavosertib and ZN-c3, reduced cell viability in all cell lines tested (IC50: 0.1–1 μM) except for TP53 wild-type SW1573, indicating that the WEE1 inhibitors may be more effective than sotorasib in KRAS-G12C-mutated NSCLC (Figures 5B and 5C). Here, KRAS is linked to non-small cell lung carcinoma.